- The Myeloma Beacon - https://myelomabeacon.org -
ImMucin
By: Jessica Langholtz; Published: October 8, 2010 @ 11:49 am | Comments Disabled
| Brand Name: | ImMucin |
| Generic Name: | |
| Code Name: | |
| Company: | Vaxil BioTherapeutics |
| FDA Clinical Phase: | 1/2 |
Description:
ImMucin is a vaccine designed to stimulate the patient’s own immune system to kill cancer cells. ImMucin is a synthetic version of the important region of the MUC1 protein, which is made by more than 90 percent of common solid tumor cancers and many non-solid tumors, including multiple myeloma. ImMucin is designed to train the immune system to detect and kill cells that have MUC1 on their surface.
Clinical Trials:
For a list of clinical trials studying ImMucin for the treatment of multiple myeloma, see ClinicalTrials.gov [1].
Official website for InMucin: http://www.vaxilbio.com/... [2]
Article printed from The Myeloma Beacon: https://myelomabeacon.org
URL to article: https://myelomabeacon.org/resources/2010/10/08/immucin/
URLs in this post:
[1] ClinicalTrials.gov: http://www.clinicaltrials.gov/ct2/results?term=ImMucin&cond=myeloma
[2] http://www.vaxilbio.com/...: http://www.vaxilbio.com/index.php?option=com_content&view=article&id=18&Itemid=27
Click here to print.
Copyright © The Beacon Foundation for Health. All rights reserved.